Healthcare
Elekta AB (publ)(EKTAY)
Live Price
Offline$5.03
-0.20% today
1Y Change
-4.30%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $20.74B
- Revenue Growth
- -0.6%
- EPS Growth
- -81.8%
- Dividend Yield
- 4.2%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Elekta AB (publ) (EKTAY) is a Healthcare stock with a market cap of $20.74B and listed on OTC. The stock last traded around $5.03 and down 4.3% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of -0.6%, EPS growth of -81.8%, a dividend yield of 4.2%. What stands out right now is revenue -0.6%, EPS -81.8%, free cash flow +29.3% with operating margin 5.4% and ROIC -2.3%. The dividend matters to the case here, with a current yield around 4.2%. Valuation is more restrained than many high-expectation growth names at price/sales 1.2. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines EKTAY price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-0.6% vs +7.6% peer median
Operating Margin
Below sector median
+5.4% vs +19.4% peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
2026 was reported on May 27, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -0.6% and EPS is at -81.8%, with operating margin around 5.4%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 4.2%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged -4.1% over the next 5 trading days and finished higher after 2 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
2026 May 27, 2026 | โ | -13.9% | -15.1% | โ |
2026 Mar 5, 2026 | โ | +10.6% | +0.7% | -4.1% |
2025 Nov 26, 2025 | โ | +4.2% | +2.1% | +5.9% |
Benchmark Edge
EKTAY vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
EKTAY
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
EKTAY Max Drawdown
-28.26%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for EKTAY and SPY.
Company Overview
Elekta AB (publ)
Other OTC
Elekta AB (publ), a medical technology company, provides clinical solutions for treating cancer and brain disorders worldwide. The company offers Versa HD, a brain metastases solution; Elekta Unity, a MR-Linac technology; Elekta Harmony, a linear accelerator; Elekta Infinity for treating a range of patients with simple-to-complex radiotherapy needs; Elekta Synergy, a digital accelerator for advanced image-guided radiation therapy; treatment management solutions; automated and integrated quality assurance solutions; and hardware and software motion management technology. It also provides MOSAIQ Plaza for multidisciplinary cancer care; Elekta Axis Cloud, a managed hosting service; Elekta Studio, an image-guided brachytherapy solution; ImagingRing, a mobile CT scanner; Oncentra Brachy, a smart tool that facilitate repetitive tasks; Venezia applicator that enables the radiation oncologist to treat locally advanced cervical cancer; Elekta Flexitron afterloader for enabling the precise execution of all steps in the workflow; and Geneva, an applicator for cervical cancer treatment. In addition, the company offers Leksell Gamma Knife Icon for personalized radiation treatment; Leksell Gamma Knife Perfexion, a tool for neurosurgeons; Leksell Gamma Knife Lightning for accelerated radiosurgery. Further, it provides neurosurgery products comprising Leksell Vantage Stereotactic System for intracranial neurosurgery; and Leksell Stereotactic System or minimally invasive stereotactic neurosurgery. The company was incorporated in 1972 and is headquartered in Stockholm, Sweden.
- Leadership
- Jakob Just-Bomholt
- IPO Date
- Mar 3, 2009
- Employees
- 4.5k
- Street Address
- Kungstensgatan 18
- Mailing
- Stockholm, 103 93
- Region
- Stockholm, SE
- Reporting Currency
- USD
- Investor Line
- 46 8 58 72 54 00
- Last Updated
- Apr 28, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- โ
- EV/EBITDA
- 14.1
- Price/Sales
- 1.2
- Price/Book
- 2.7
Growth
- Revenue
- -0.6%
- EPS
- -81.8%
- Free Cash Flow
- +29.3%
Profitability
- Gross Margin
- 37.5%
- Operating Margin
- 5.4%
- Net Margin
- -0.2%
- ROE
- -0.5%
- ROIC
- -2.3%
Balance Sheet
- Debt/Equity
- 0.91
- Current Ratio
- 0.95
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.